Markets open

Koninklijke Philips N.V. NY Registry Shares

PHG · NYSE

Analyst Consensus

Hold

7 analysts

$30

Current

—

Low

$27

Average

—

High

Average target implies -9.43% versus the current price.

Analyst Ratings Synthesis

A consensus rating, analyst count and target range cannot be established from the supplied evidence. The only explicit targets are Morgan Stanley’s EUR 22, reduced from EUR 24, and a Seeking Alpha author’s cut to $25.76 per ADR; the latter is not attributed to a named research firm, so these figures do not define a comparable target cluster or spread. UBS analyst Graham Doyle upgraded Philips from Neutral to Buy, while Morgan Stanley’s Aisyah Noor maintained Equal Weight and cut the target. The Seeking Alpha author also downgraded, but the snippet does not identify the author’s firm. No analyst actions are dated within the week, so the direction of revisions over the week is unknown. The substantive divide is recovery potential versus continuing operating and regulatory risks.

Rating Actions

No individual rating actions have been captured for PHG yet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

CITIGROUP

GOLDMAN SACHS

JEFFERIES & CO.

JP MORGAN SECUR

UBS

ZACKS RESEARCH

Symbol: PHG
Type: Stock
Sector: Health Care
Industry: Medical Electronics
Country: Europe
Exchange: NYSE

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in image-guided therapy, diagnostic imaging, ultrasound, monitoring, enterprise informatics and personal health. Philips generated 2025 sales of approximately EUR 18 billion and employs approximately 63,900 employees with sales and services in more than 100 countries.

Key Issues

Bullish view

A Seeking Alpha analysis says the recovery is real, supporting the view that operational improvement is underway.

Bearish view

The same analysis says operational and regulatory risks have not diminished, citing China exposure, sleep-segment recovery and minor litigation, and its author downgraded the shares.